Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

The National Joint Procurement Office issued the Announcement on the Information Change Work for Selected Products in National Organization of Drug Volume‑Based Procurement, permitting – when selected enterprises and their…

Genentech's Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

Genentech’s Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

HutchMed's Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

HutchMed’s Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
CompanyDeals

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
CompanyDrug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Konruns Doses First Patient in Phase 2 Esophageal Cancer Trial for KC1036
CompanyDrug

Konruns Doses First Patient in Phase 2 Esophageal Cancer Trial for KC1036

Johnson & Johnson's TECVAYLI Gets FDA Priority Review for Myeloma Combo
CompanyDrug

Johnson & Johnson’s TECVAYLI Gets FDA Priority Review for Myeloma Combo

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline
CompanyDrug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market
CompanyDrug

Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market

InnoCare's Zurletrectinib Wins NMPA Nod as China's First Next-Gen TRK Inhibitor
CompanyDrug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer
CompanyDrug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Show More